Taysha Gene Therapies announced its Q3 2026 financial results and updates on its TSHA-102 gene therapy for Rett syndrome, highlighting ongoing REVEAL pivotal and ASPIRE trials with no severe adverse events reported. The company completed a key manufacturing campaign meeting FDA standards, supporting a potential Biologics License Application (BLA) submission. Topline data from a 6-month interim analysis and FDA feedback on the BLA pathway are expected in the first half of 2027, alongside plans to nominate a second gene therapy candidate. Taysha reported a net loss of $39.1 million for Q3 2026 but holds $422.8 million in cash, supporting operations into late 2028.
Taysha Gene Therapies' Q3 2026 results provide context for health sector trends. For readers following health stocks, 91 of 150 US health stocks on Pluang rose while 53 fell. MMED traded at USD 17.50 with a 4.11% decline; MRVI rose 3.12% to USD 7.94 with 55% sell orders; TWST dropped 3.12% to USD 118.77 with 100% buy orders. Data is as of Nov 12, 2026 19:11 WIB.
Evaxion, a clinical-stage TechBio company, has released its financial calendar for 2027, outlining important dates for business updates and financial results. Key events include the full year 2026 results on March 4, the Annual General Meeting on Apr...
CollPlant Biotechnologies will change its Nasdaq ticker from CLGN to OPHI starting November 13, 2026, reflecting its strategic shift toward photonic computing through its subsidiary LightSolver. This move highlights CollPlant's focus on developing Li...
Glider has introduced a global investing platform for tokenized stocks that operates permissionlessly, bypassing the SEC's Tokenized Securities Venues (TSVs) which 50 public companies recently rejected. Backed by major investors like a16z and Coinbas...
BofA Securities raised its price target for Royal Caribbean Group to $365, citing strong booking volumes and the company’s goal of adjusted earnings per share around $20 by 2027. The cruise operator expects 4.5% capacity growth next year and has repo...
Tilray Brands announced that its subsidiaries 10 Barrel Brewing, Widmer Brothers Brewing, and Hop Valley Brewing are now the official craft beer partners of the Portland Trail Blazers. This partnership expands the availability of Oregon craft beers a...
